These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 9598479

  • 21. Role of NMP22 Bladder Check Test in early detection of bladder cancer with recurrence.
    Kundal VK, Pandith AA, Hamid A, Shah A, Kundal R, Wani SM.
    Asian Pac J Cancer Prev; 2010; 11(5):1279-82. PubMed ID: 21198277
    [Abstract] [Full Text] [Related]

  • 22. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence.
    Boman H, Hedelin H, Holmäng S.
    J Urol; 2002 Jan; 167(1):80-3. PubMed ID: 11743280
    [Abstract] [Full Text] [Related]

  • 23. Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder.
    Babjuk M, Kostírová M, Mudra K, Pecher S, Smolová H, Pecen L, Ibrahim Z, Dvorácek J, Jarolím L, Novák J, Zima T.
    Eur Urol; 2002 Jan; 41(1):34-9. PubMed ID: 11999463
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Performance characteristics of multiple urinary tumor markers and sample collection techniques in the detection of transitional cell carcinoma of the bladder.
    Bhuiyan J, Akhter J, O'Kane DJ.
    Clin Chim Acta; 2003 May; 331(1-2):69-77. PubMed ID: 12691866
    [Abstract] [Full Text] [Related]

  • 27. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM, García Rodríguez J, Escaf Barmadah S, Raigoso P, Rodríguez Martínez JJ, Allende MT, Casasola Chamorro J, Rodríguez Faba O, Martín Benito JL, Regadera Sejas FJ.
    Arch Esp Urol; 2002 May; 55(1):41-9. PubMed ID: 11957750
    [Abstract] [Full Text] [Related]

  • 28. Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder.
    Mian C, Lodde M, Haitel A, Vigl EE, Marberger M, Pycha A.
    Urology; 2000 Feb; 55(2):223-6. PubMed ID: 10688083
    [Abstract] [Full Text] [Related]

  • 29. Evaluation of the clinical value of urinary NMP22 as a marker in the screening and surveillance of transitional cell carcinoma of the urinary bladder.
    Chahal R, Darshane A, Browning AJ, Sundaram SK.
    Eur Urol; 2001 Oct; 40(4):415-20; discussion 421. PubMed ID: 11713396
    [Abstract] [Full Text] [Related]

  • 30. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer.
    Leyh H, Marberger M, Conort P, Sternberg C, Pansadoro V, Pagano F, Bassi P, Boccon-Gibod L, Ravery V, Treiber U, Ishak L.
    Eur Urol; 1999 Jan; 35(1):52-6. PubMed ID: 9933795
    [Abstract] [Full Text] [Related]

  • 31. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
    Gilbert SM, Veltri RW, Sawczuk A, Shabsigh A, Knowles DR, Bright S, O'Dowd GJ, Olsson CA, Benson MC, Sawczuk IS.
    Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC.
    Sawczuk IS, Pickens CL, Vasa UR, Ralph DA, Norris KA, Miller MC, Ng AY, Grossman HB, Veltri RW.
    Urol Oncol; 2002 Mar; 7(5):185-90. PubMed ID: 12644214
    [Abstract] [Full Text] [Related]

  • 35. Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer.
    Lee KH.
    Yonsei Med J; 2001 Feb; 42(1):14-8. PubMed ID: 11293494
    [Abstract] [Full Text] [Related]

  • 36. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
    Friedrich MG, Hellstern A, Hautmann SH, Noldus I, Huland H.
    Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
    [Abstract] [Full Text] [Related]

  • 37. Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)--useful diagnostic tools in the diagnosis of urinary bladder cancer?
    Mahnert B, Tauber S, Kriegmair M, Nagel D, Holdenrieder S, Hofmann K, Reiter W, Schmeller N, Stieber P.
    Clin Chem Lab Med; 2003 Jan; 41(1):104-10. PubMed ID: 12636058
    [Abstract] [Full Text] [Related]

  • 38. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment.
    Soloway MS, Briggman V, Carpinito GA, Chodak GW, Church PA, Lamm DL, Lange P, Messing E, Pasciak RM, Reservitz GB, Rukstalis DB, Sarosdy MF, Stadler WM, Thiel RP, Hayden CL.
    J Urol; 1996 Aug; 156(2 Pt 1):363-7. PubMed ID: 8683680
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer.
    Abd El Gawad IA, Moussa HS, Nasr MI, El Gemae EH, Masooud AM, Ibrahim IK, El Hifnawy NM.
    J Egypt Natl Canc Inst; 2005 Sep; 17(3):193-202. PubMed ID: 16799657
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.